欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (11): 1278-1282.

• 药物治疗学 • 上一篇    下一篇

阿奇霉素联合盐酸氨溴索治疗小儿支原体肺炎合并急性支气管炎的临床研究

罗玲玲,滕承志,李晓笑,潘丹峰   

  1. 温岭市第一人民医院,儿科三,温岭 317500,浙江
  • 收稿日期:2017-05-22 修回日期:2017-06-09 出版日期:2017-11-26 发布日期:2017-12-11
  • 作者简介:罗玲玲,女,本科,主治医师,儿科常见病的诊治,儿童危急重症的抢救和诊治。 E-mail:14763952591@163.com
  • 基金资助:

    温岭市科技局项目(2010WLCA0061)

Clinical trial of azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia

LUO Lingling, TENG Chengzhi, LI Xiaoxiao, PAN Danfeng   

  1. Department of Third Pediatrics, the First Affiliated Hospital of Wenling City, Wenling 317500,Zhejiang, China
  • Received:2017-05-22 Revised:2017-06-09 Online:2017-11-26 Published:2017-12-11

摘要:

目的:观察阿奇霉素联合盐酸氨溴索治疗小儿支原体肺炎合并急性支气管炎的临床疗效和安全性。方法: 将104例小儿支原体肺炎合并急性支气管炎患儿随机分为对照组和试验组,每组52例。对照组给予阿奇霉素10 mg/kg,qd,静脉滴注;试验组给予阿奇霉素10 mg/kg+盐酸氨溴索15 mg,qd,静脉滴注,连读给药7 d。观察两组临床疗效和不良反应,比较两组患儿的血清超敏C-反应蛋白(hsCRP)、γ-干扰素(IFN-γ)、降钙素原(PCT)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)水平。结果: 试验组和对照组总有效率分别为96.15%(50/52例)和82.69%(43/52例),差异有统计学意义(P<0.05)。试验组和对照组的hsCRP分别为(13.28±4.76)和(21.11±6.42)mg/L;IFN-γ分别为(8.45±3.62)和(20.36±5.12)ng/L;PCT分别为(4.02±2.07)和(7.46±2.13)μg/L;IgA分别为(2.17±0.43)和(4.03±0.52)μg/L;IgG分别为(8.14±1.31)和(12.32±1.65)μg/L;IgM分别为(0.86±0.28)和(1.20±0.39)μg/L;差异均有统计学意义(P<0.05)。药物不良反应主要为恶心、呕吐、皮疹、腹泻、头晕、嗜睡等,试验组和对照组药物不良反应发生率分别为23.08%和19.23%(P>0.05)。 结论:阿奇霉素联合盐酸氨溴素治疗小儿支原体肺炎合并急性支气管炎临床疗效明确,可减轻患儿的炎症反应,改善免疫功能,且安全性较好。

关键词: 阿奇霉素, 盐酸氨溴索, 支原体肺炎, 急性支气管炎, 炎症因子, 免疫功能

Abstract:

AIM: To observe the clinical efficacy and safety of azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia.  METHODS: One hundred and four mycoplasma pneumonia children with bronchial pneumonia were randomly divided into control group and treatment group, fifty-two cases for each group. The control group was given azithromycin 10 mg/kg, qd, intravenous drip; and the treatment group was given azithromycin 10 mg/kg+ambroxol hydrochloride 15 mg, qd, intravenous drip. After 7d treatment, the clinical efficacy and occurrence of adverse drug reactions were observed. The levels of serum hypersensitive C-creactive protein (hsCRP), gamma interferon (IFN-γ), procalcitonin (PCT), immunoglobulin A(IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) were compared. RESULTS:After 7 d treatment, the total effective rate in treatment group and control group were 96.15%(50/52) and 82.69%(43/52), the difference was statistically significant (P<0.05). The hsCRP of treatment group and control group were (13.28±4.76) and (21.11±6.42) mg/L; IFN-γ were (8.45±3.62) and (20.36±5.12) ng/L; PCT were (4.02±2.07) and (7.46±2.13) μg/L; IgA were (2.17±0.43) and (4.03±0.52) μg/L; IgG were (8.14±1.31) and (12.32±1.65) μg/L; IgM were (0.86±0.28) and (1.20±0.39) μg/L, respectively, the differences were all statistically significant (P<0.05). The adverse drug reactions were mainly nausea, vomiting, rash, diarrhea, dizziness, drowsiness, the incidence of adverse drug reactions in treatment group and control group were 23.08% and 19.23%, respectively, the difference has no statistically significant difference (P>0.05). CONCLUSION: The azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia have significantly curative effect, which can reduce the patients' inflammation, improve immune function, and have no increasing the adverse drug reactions.

Key words: azithromycin, ambroxol hydrochloride, mycoplasma pneumonia, acute bronchial pneumonia, inflammation factors, immune function

中图分类号: